Astellas Pharma Gmbh

Kotobuki Pharmaceutical Co Ltd

Norio Asai

Toshihiro Watanabe

Takafumi Shimizu

Daisuke Yamashita

Hiroyuki Moritomo

Satoshi Miyamoto

Hiroyuki Koshio

Takashi Sugane

Hironori Harada

Yasuhiro Yonetoku

Kazuhiro Ikegai

Taisuke Takahashi

Noriko Ishikawa

Shohei Shirakami

Naomi Hosogai

Seijiro Akamatsu

Tetsuo Kiso

Takahiro Kuramochi

Yasuhito Nagai

Keiko Kawabata

Karl Bruce Thor

Shigeru Yoshida

Hiroshi Tomiyama

Keizo Sugasawa

Kenji Negoro

Takatoshi Soga

Kyoichi Maeno

Jiro Fujiyasu

Takuya Makino

Yoshinori Iwai

Kei Ohnuki

Makoto Oku

Motoharu Sonegawa

Daisuke Tanabe

Hisashi Mihara

Toshio Kurosaki

Fumiyoshi Iwasaki

Kazuo Tokuzaki

Kazumi Kikuchi

Kazuhiko Osoda

Yukinori Nagakura

[Problem] To provide a compound useful as an MCreceptor agonist. [Means for Solution] The present inventors studied MCreceptor agonists, and have found that a piperazine derivative has an MCreceptor agonistic action, thereby completing the present invention. The piperazine derivative of the present invention has an MCreceptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Piperazine derivative

To provide a compound which can be used as an MCreceptor agonist. The present inventors have investigated MCreceptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MCreceptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Provided is a compound which is useful as an agent for treating or preventing 5-HTreceptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HTreceptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HTreceptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HTreceptor agonist activity and can be used as an agent for treating or preventing 5-HTreceptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Benzazepine compound

The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.

Nitrogen&#x2014;containing heterocyclic derivatives having 2,6-disubstituted styryl

A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.

Oxadiazolidinedione compound

There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).

Benzamide derivative or salt thereof

Growing community of inventors

Tokyo, Japan

Norio Asai